RxDoctor Payments Data

Barbara Pierce, MD

Family Medicine · College Station, TXNPI 1477653962

Payments from drug & device makers

$569in general payments, 2019–2025

Across 9 payments — averaging $63.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245
  • Amgen$175
  • Lilly USA, LLC$87
  • Dexcom, Inc.$47
  • AbbVie$16

What the payments were for

  • Consulting fees$17531%
  • Food & beverage$39469%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$245
Amgen1$175
Lilly USA, LLC1$87
Dexcom, Inc.3$47
AbbVie1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$569 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$210,004
Medicare patients
568
Services billed
3,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$131,584
EliquisApixaban122$104,092
OzempicSemaglutide94$94,138
FarxigaDapagliflozin Propanediol74$61,400
TrulicityDulaglutide44$53,339
JanuviaSitagliptin Phosphate29$41,400
JardianceEmpagliflozin43$40,033
XareltoRivaroxaban44$34,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,350
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$16,567
Soliqua 100-33Insulin Glargine/Lixisenatide13$14,653
LinzessLinaclotide17$13,064
MyrbetriqMirabegron25$12,815
Janumet XrSitagliptin Phos/Metformin Hcl27$12,413
Rosuvastatin Calcium586$9,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$87$184,923162 claims
Novo NordiskOzempic$245$94,13894 claims
AbbVieLinzess, Synthroid$16$17,52788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in College Station

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →